Eli Lilly Reaps Benefits from Weight Loss Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Weight Loss Drug Success: Eli Lilly's weight loss treatment is performing exceptionally well in the market, driving significant growth in the company's performance and expected to enhance its competitive edge in the pharmaceutical industry.
- Investment Recommendation Analysis: Despite Eli Lilly's strong performance in the weight loss drug sector, it was not included in the current best stock picks by The Motley Fool Stock Advisor analyst team, indicating a cautious market outlook on its future growth.
- Historical Investment Returns: Looking back, Netflix and Nvidia were featured on The Motley Fool's recommendation list, where a $1,000 investment at the time would now be worth $382,359 and $1,201,390 respectively, showcasing the platform's investment potential.
- Market Performance Comparison: As of June 26, 2026, The Motley Fool Stock Advisor's total average return stands at 883%, significantly outperforming the S&P 500's 205%, reflecting the effectiveness of its stock selection strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1127.690
Low
950.00
Averages
1192
High
1500
Current: 1127.690
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reaps Benefits from Weight Loss Drug
- Weight Loss Drug Success: Eli Lilly's weight loss treatment is performing exceptionally well in the market, driving significant growth in the company's performance and expected to enhance its competitive edge in the pharmaceutical industry.
- Investment Recommendation Analysis: Despite Eli Lilly's strong performance in the weight loss drug sector, it was not included in the current best stock picks by The Motley Fool Stock Advisor analyst team, indicating a cautious market outlook on its future growth.
- Historical Investment Returns: Looking back, Netflix and Nvidia were featured on The Motley Fool's recommendation list, where a $1,000 investment at the time would now be worth $382,359 and $1,201,390 respectively, showcasing the platform's investment potential.
- Market Performance Comparison: As of June 26, 2026, The Motley Fool Stock Advisor's total average return stands at 883%, significantly outperforming the S&P 500's 205%, reflecting the effectiveness of its stock selection strategy.
See More
Opportunity to Buy Quality Stocks at Low Prices
- Market Opportunity: Investors have the chance to buy quality stocks at low prices based on afternoon prices from June 24, 2026, which may create a solid foundation for future investment returns.
- Investor Sentiment: The video published on June 26, 2026, reflects an optimistic attitude among investors regarding the current market conditions, believing that low-priced stocks will yield potential appreciation opportunities.
- Price Volatility Analysis: The timing of purchasing low-priced stocks may be related to overall market trends, prompting investors to monitor market dynamics to seize the best entry points for capital appreciation.
- Long-term Investment Strategy: The strategy of buying quality stocks at low prices may offer investors the potential for long-term gains, especially during market recoveries, effectively enhancing the overall performance of their investment portfolios.
See More
Eli Lilly Gains from Blockbuster Weight Loss Drug
- Weight Loss Drug Performance: Eli Lilly's weight loss treatment is performing strongly in the market, driving stock prices up by 7.51% on June 24, 2026, indicating robust consumer demand and market acceptance.
- Significant Financial Impact: The success of this drug not only boosts overall company revenue but is also expected to significantly improve profit margins in the coming quarters, thereby enhancing investor confidence and market expectations.
- Strategic Positioning: By launching this blockbuster weight loss drug, Eli Lilly has solidified its leadership position in the rapidly growing weight loss market, which is likely to attract more investment and R&D resources to support future product innovations.
- Optimistic Market Outlook: With the continued success of the weight loss drug, Eli Lilly is poised for sustainable growth in the coming years, further expanding its market share and influence within the pharmaceutical industry.
See More
Analysts Recommend Top 10 Stocks to Buy Now
- Investment Opportunity: The analyst team has identified the top 10 stocks as the best investment choices at current low prices, which could yield substantial returns in the coming years, drawing investor interest.
- Historical Returns: For instance, a $1,000 investment in Netflix back in December 2004 would have grown to $382,359 today, while a similar investment in Nvidia from April 2005 would now be worth $1,201,390, highlighting the potential value of these stocks.
- Market Performance: Stock Advisor boasts an impressive average return of 883%, significantly outperforming the S&P 500's 205%, indicating the effectiveness and competitiveness of its investment strategies.
- Community Support: By joining Stock Advisor, investors gain access to the latest top 10 stock recommendations and become part of an investing community built by individual investors, enhancing confidence and support in their investment decisions.
See More
Eli Lilly Shares Reach Record High Following Positive Drug Developments
- Oncology Progress: The European Medicines Agency issued a positive opinion for Eli Lilly's cancer drug Jaypirca, which has shown promising results in treating chronic lymphocytic leukemia (CLL), paving the way for potential regulatory approval and new market opportunities for the company.
- Market Potential: CLL is a common type of leukemia in adults, with approximately 100,000 new cases annually worldwide; the success of Jaypirca could significantly enhance Eli Lilly's market share in oncology treatments.
- New Weight Loss Opportunities: Eli Lilly announced that its obesity drugs Zepbound and Foundayo will be available through the new Medicare GLP-1 Bridge program starting July 1 for as low as $50 per month, marking a significant milestone in the coverage of weight management medications and potentially attracting around 20 million eligible Medicare patients.
- Strategic Implications: This policy implementation not only makes obesity treatment accessible for many for the first time but also positions Eli Lilly to strengthen its leadership in the obesity drug market, further enhancing its competitive edge in the healthcare industry.
See More
Eli Lilly's Leukemia Drug Receives Positive EU Opinion
- Regulatory Progress: Eli Lilly's leukemia drug Jaypirca has received a positive opinion from the European Medicines Agency, with clinical trials demonstrating significant efficacy in treating chronic lymphocytic leukemia (CLL), and the European Commission is expected to make a final decision within two months, paving the way for market launch.
- Market Potential: With approximately 100,000 adult CLL cases annually worldwide, Jaypirca is poised to address this substantial market demand, further solidifying Eli Lilly's leadership position in oncology treatments.
- Increased Accessibility for Weight Loss Drugs: Eli Lilly announced that its obesity drugs Zepbound and Foundayo will be available through the new Medicare GLP-1 Bridge program starting July 1 for as low as $50 per month, enabling around 20 million Medicare patients who meet clinical criteria to access weight management treatments for the first time.
- Strategic Implications: This policy marks a significant expansion in the coverage of weight loss medications, potentially enhancing Eli Lilly's market share in obesity treatment while also reflecting the company's commitment to public health and market responsiveness.
See More
Eli Lilly Reaps Benefits from Weight Loss Drug
- Weight Loss Drug Success: Eli Lilly's weight loss treatment is performing exceptionally well in the market, driving significant growth in the company's performance and expected to enhance its competitive edge in the pharmaceutical industry.
- Investment Recommendation Analysis: Despite Eli Lilly's strong performance in the weight loss drug sector, it was not included in the current best stock picks by The Motley Fool Stock Advisor analyst team, indicating a cautious market outlook on its future growth.
- Historical Investment Returns: Looking back, Netflix and Nvidia were featured on The Motley Fool's recommendation list, where a $1,000 investment at the time would now be worth $382,359 and $1,201,390 respectively, showcasing the platform's investment potential.
- Market Performance Comparison: As of June 26, 2026, The Motley Fool Stock Advisor's total average return stands at 883%, significantly outperforming the S&P 500's 205%, reflecting the effectiveness of its stock selection strategy.
See More
Opportunity to Buy Quality Stocks at Low Prices
- Market Opportunity: Investors have the chance to buy quality stocks at low prices based on afternoon prices from June 24, 2026, which may create a solid foundation for future investment returns.
- Investor Sentiment: The video published on June 26, 2026, reflects an optimistic attitude among investors regarding the current market conditions, believing that low-priced stocks will yield potential appreciation opportunities.
- Price Volatility Analysis: The timing of purchasing low-priced stocks may be related to overall market trends, prompting investors to monitor market dynamics to seize the best entry points for capital appreciation.
- Long-term Investment Strategy: The strategy of buying quality stocks at low prices may offer investors the potential for long-term gains, especially during market recoveries, effectively enhancing the overall performance of their investment portfolios.
See More
Eli Lilly Gains from Blockbuster Weight Loss Drug
- Weight Loss Drug Performance: Eli Lilly's weight loss treatment is performing strongly in the market, driving stock prices up by 7.51% on June 24, 2026, indicating robust consumer demand and market acceptance.
- Significant Financial Impact: The success of this drug not only boosts overall company revenue but is also expected to significantly improve profit margins in the coming quarters, thereby enhancing investor confidence and market expectations.
- Strategic Positioning: By launching this blockbuster weight loss drug, Eli Lilly has solidified its leadership position in the rapidly growing weight loss market, which is likely to attract more investment and R&D resources to support future product innovations.
- Optimistic Market Outlook: With the continued success of the weight loss drug, Eli Lilly is poised for sustainable growth in the coming years, further expanding its market share and influence within the pharmaceutical industry.
See More
Analysts Recommend Top 10 Stocks to Buy Now
- Investment Opportunity: The analyst team has identified the top 10 stocks as the best investment choices at current low prices, which could yield substantial returns in the coming years, drawing investor interest.
- Historical Returns: For instance, a $1,000 investment in Netflix back in December 2004 would have grown to $382,359 today, while a similar investment in Nvidia from April 2005 would now be worth $1,201,390, highlighting the potential value of these stocks.
- Market Performance: Stock Advisor boasts an impressive average return of 883%, significantly outperforming the S&P 500's 205%, indicating the effectiveness and competitiveness of its investment strategies.
- Community Support: By joining Stock Advisor, investors gain access to the latest top 10 stock recommendations and become part of an investing community built by individual investors, enhancing confidence and support in their investment decisions.
See More
Eli Lilly Shares Reach Record High Following Positive Drug Developments
- Oncology Progress: The European Medicines Agency issued a positive opinion for Eli Lilly's cancer drug Jaypirca, which has shown promising results in treating chronic lymphocytic leukemia (CLL), paving the way for potential regulatory approval and new market opportunities for the company.
- Market Potential: CLL is a common type of leukemia in adults, with approximately 100,000 new cases annually worldwide; the success of Jaypirca could significantly enhance Eli Lilly's market share in oncology treatments.
- New Weight Loss Opportunities: Eli Lilly announced that its obesity drugs Zepbound and Foundayo will be available through the new Medicare GLP-1 Bridge program starting July 1 for as low as $50 per month, marking a significant milestone in the coverage of weight management medications and potentially attracting around 20 million eligible Medicare patients.
- Strategic Implications: This policy implementation not only makes obesity treatment accessible for many for the first time but also positions Eli Lilly to strengthen its leadership in the obesity drug market, further enhancing its competitive edge in the healthcare industry.
See More
Eli Lilly's Leukemia Drug Receives Positive EU Opinion
- Regulatory Progress: Eli Lilly's leukemia drug Jaypirca has received a positive opinion from the European Medicines Agency, with clinical trials demonstrating significant efficacy in treating chronic lymphocytic leukemia (CLL), and the European Commission is expected to make a final decision within two months, paving the way for market launch.
- Market Potential: With approximately 100,000 adult CLL cases annually worldwide, Jaypirca is poised to address this substantial market demand, further solidifying Eli Lilly's leadership position in oncology treatments.
- Increased Accessibility for Weight Loss Drugs: Eli Lilly announced that its obesity drugs Zepbound and Foundayo will be available through the new Medicare GLP-1 Bridge program starting July 1 for as low as $50 per month, enabling around 20 million Medicare patients who meet clinical criteria to access weight management treatments for the first time.
- Strategic Implications: This policy marks a significant expansion in the coverage of weight loss medications, potentially enhancing Eli Lilly's market share in obesity treatment while also reflecting the company's commitment to public health and market responsiveness.
See More
